Cynata Therapeutics Management
Management criteria checks 3/4
Cynata Therapeutics' CEO is Kilian Kelly, appointed in Jul 2023, has a tenure of 1.42 years. total yearly compensation is A$544.83K, comprised of 71.7% salary and 28.3% bonuses, including company stock and options. directly owns 0.34% of the company’s shares, worth A$123.93K. The average tenure of the management team and the board of directors is 2.3 years and 4.5 years respectively.
Key information
Kilian Kelly
Chief executive officer
AU$544.8k
Total compensation
| CEO salary percentage | 71.7% |
| CEO tenure | 1.4yrs |
| CEO ownership | 0.3% |
| Management average tenure | 2.3yrs |
| Board average tenure | 4.5yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | AU$545k | AU$391k | -AU$10m |
| Mar 31 2024 | n/a | n/a | -AU$12m |
| Dec 31 2023 | n/a | n/a | -AU$14m |
| Sep 30 2023 | n/a | n/a | -AU$14m |
| Jun 30 2023 | AU$413k | AU$334k | -AU$14m |
| Mar 31 2023 | n/a | n/a | -AU$12m |
| Dec 31 2022 | n/a | n/a | -AU$9m |
| Sep 30 2022 | n/a | n/a | -AU$7m |
| Jun 30 2022 | AU$499k | AU$313k | -AU$5m |
| Mar 31 2022 | n/a | n/a | -AU$5m |
| Dec 31 2021 | n/a | n/a | -AU$4m |
| Sep 30 2021 | n/a | n/a | -AU$6m |
| Jun 30 2021 | AU$737k | AU$300k | -AU$8m |
| Mar 31 2021 | n/a | n/a | -AU$7m |
| Dec 31 2020 | n/a | n/a | -AU$6m |
| Sep 30 2020 | n/a | n/a | -AU$5m |
| Jun 30 2020 | AU$472k | AU$300k | -AU$4m |
| Mar 31 2020 | n/a | n/a | -AU$6m |
| Dec 31 2019 | n/a | n/a | -AU$8m |
| Sep 30 2019 | n/a | n/a | -AU$8m |
| Jun 30 2019 | AU$449k | AU$279k | -AU$8m |
| Mar 31 2019 | n/a | n/a | -AU$7m |
| Dec 31 2018 | n/a | n/a | -AU$6m |
| Sep 30 2018 | n/a | n/a | -AU$5m |
| Jun 30 2018 | AU$357k | AU$259k | -AU$5m |
Compensation vs Market: Kilian's total compensation ($USD340.75K) is about average for companies of similar size in the Australian market ($USD291.28K).
Compensation vs Earnings: Kilian's compensation has increased whilst the company is unprofitable.
CEO
Kilian Kelly
1.4yrs
Tenure
AU$544,827
Compensation
Dr. Kilian Kelly has been Chief Executive Officer and Managing Director at Cynata Therapeutics Limited since July 1, 2023 and has been its Director since 2023 and had been its Chief Operating Officer since...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, CEO & Director | 1.4yrs | AU$544.83k | 0.34% A$ 123.9k | |
| Chief Medical Officer | 3.2yrs | AU$398.72k | no data | |
| Chief Business Officer | less than a year | AU$379.02k | no data | |
| Company Secretary | 12.7yrs | AU$140.00k | no data |
2.3yrs
Average Tenure
Experienced Management: CYP's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, CEO & Director | 1.9yrs | AU$544.83k | 0.34% A$ 123.9k | |
| Independent Non-Executive Chairman | 5.6yrs | AU$138.77k | 0.14% A$ 51.5k | |
| Independent Non-Executive Director | 8.5yrs | AU$68.20k | 0.17% A$ 63.1k | |
| Independent Non-Executive Director | 2.3yrs | AU$81.69k | 0.064% A$ 23.3k | |
| Independent Non-Executive Director | 4.5yrs | AU$68.20k | 0.028% A$ 10.0k |
4.5yrs
Average Tenure
64yo
Average Age
Experienced Board: CYP's board of directors are considered experienced (4.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 14:59 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cynata Therapeutics Limited is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dennis Hulme | APP Securities Pty Ltd. |
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Chris Kallos | MST Financial Services Pty Limited |